In vivo and in vitro regulation of IgE production in murine hybridomas

A. Mathur, B. G. Van Ness, R. G. Lynch

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Normal BALB/c mice injected i.p. with the IgE-secreting hybridomas B53 (ε,κ, anti-DNP), SE1.3 (ε,κ, anti-arsonate) or A3B1 (ε,κ, anti-TNP) were monitored for serum IgE concentrations and frequencies of splenic T lymphocytes with surface membrane receptors for the Fc portion of IgE (FcεR+ T lymphocytes). Mice with B53 or SE1.3 hybridomas initially developed high concentrations of IgE and CD8+ FcεR+ T lymphocytes, followed by a progressive decline in both serum IgE and expression of cytoplasmic ε-chains in the hybridoma cells. Serum IgE concentrations in mice with A3B1 hybridomas progressively increased without development of FcεR+ T lymphocytes nor a subsequent decline in IgE or change in cytoplasmic ε-chain expression in the A3B1 cells. An in vitro system in which the IgE-secreting hybridoma cells were cocultured with spleen cells harvested from mice with established B53 tumors was used to investigate the mechanisms involved in the inhibition of IgE production by the hybridoma cells. The results of these studies indicate: 1) the induction/upregulation of FcεR on CD8+ T lymphocytes in vivo requires factors in addition to high serum IgE concentrations; 2) in addition to CD8+ FcεR+ T lymphocytes and monocytes, another, as yet unidentified, splenic cell component appears to contribute to the process by which ε-chain expression in IgE-secreting hybridoma cells is suppressed, and 3) a hybridoma (A3B1) that fails to induce CD8+, FcεR+ T lymphocytes in vivo and is not inhibited in IgE expression in vivo, nonetheless is inhibited in IgE expression in vitro when cocultured with spleen cells from mice with B53 tumors.

Original languageEnglish (US)
Pages (from-to)3610-3617
Number of pages8
JournalJournal of Immunology
Volume145
Issue number11
StatePublished - Jan 1 1990

Fingerprint

Hybridomas
Immunoglobulin E
T-Lymphocytes
Serum
In Vitro Techniques
Spleen
Fc Receptors
Cellular Structures
Monocytes
Neoplasms
Up-Regulation

Cite this

In vivo and in vitro regulation of IgE production in murine hybridomas. / Mathur, A.; Van Ness, B. G.; Lynch, R. G.

In: Journal of Immunology, Vol. 145, No. 11, 01.01.1990, p. 3610-3617.

Research output: Contribution to journalArticle

Mathur, A. ; Van Ness, B. G. ; Lynch, R. G. / In vivo and in vitro regulation of IgE production in murine hybridomas. In: Journal of Immunology. 1990 ; Vol. 145, No. 11. pp. 3610-3617.
@article{a8c87e0869524d6fabffff1d45f7817c,
title = "In vivo and in vitro regulation of IgE production in murine hybridomas",
abstract = "Normal BALB/c mice injected i.p. with the IgE-secreting hybridomas B53 (ε,κ, anti-DNP), SE1.3 (ε,κ, anti-arsonate) or A3B1 (ε,κ, anti-TNP) were monitored for serum IgE concentrations and frequencies of splenic T lymphocytes with surface membrane receptors for the Fc portion of IgE (FcεR+ T lymphocytes). Mice with B53 or SE1.3 hybridomas initially developed high concentrations of IgE and CD8+ FcεR+ T lymphocytes, followed by a progressive decline in both serum IgE and expression of cytoplasmic ε-chains in the hybridoma cells. Serum IgE concentrations in mice with A3B1 hybridomas progressively increased without development of FcεR+ T lymphocytes nor a subsequent decline in IgE or change in cytoplasmic ε-chain expression in the A3B1 cells. An in vitro system in which the IgE-secreting hybridoma cells were cocultured with spleen cells harvested from mice with established B53 tumors was used to investigate the mechanisms involved in the inhibition of IgE production by the hybridoma cells. The results of these studies indicate: 1) the induction/upregulation of FcεR on CD8+ T lymphocytes in vivo requires factors in addition to high serum IgE concentrations; 2) in addition to CD8+ FcεR+ T lymphocytes and monocytes, another, as yet unidentified, splenic cell component appears to contribute to the process by which ε-chain expression in IgE-secreting hybridoma cells is suppressed, and 3) a hybridoma (A3B1) that fails to induce CD8+, FcεR+ T lymphocytes in vivo and is not inhibited in IgE expression in vivo, nonetheless is inhibited in IgE expression in vitro when cocultured with spleen cells from mice with B53 tumors.",
author = "A. Mathur and {Van Ness}, {B. G.} and Lynch, {R. G.}",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "145",
pages = "3610--3617",
journal = "Journal of Immunology",
issn = "0022-1767",
publisher = "American Association of Immunologists",
number = "11",

}

TY - JOUR

T1 - In vivo and in vitro regulation of IgE production in murine hybridomas

AU - Mathur, A.

AU - Van Ness, B. G.

AU - Lynch, R. G.

PY - 1990/1/1

Y1 - 1990/1/1

N2 - Normal BALB/c mice injected i.p. with the IgE-secreting hybridomas B53 (ε,κ, anti-DNP), SE1.3 (ε,κ, anti-arsonate) or A3B1 (ε,κ, anti-TNP) were monitored for serum IgE concentrations and frequencies of splenic T lymphocytes with surface membrane receptors for the Fc portion of IgE (FcεR+ T lymphocytes). Mice with B53 or SE1.3 hybridomas initially developed high concentrations of IgE and CD8+ FcεR+ T lymphocytes, followed by a progressive decline in both serum IgE and expression of cytoplasmic ε-chains in the hybridoma cells. Serum IgE concentrations in mice with A3B1 hybridomas progressively increased without development of FcεR+ T lymphocytes nor a subsequent decline in IgE or change in cytoplasmic ε-chain expression in the A3B1 cells. An in vitro system in which the IgE-secreting hybridoma cells were cocultured with spleen cells harvested from mice with established B53 tumors was used to investigate the mechanisms involved in the inhibition of IgE production by the hybridoma cells. The results of these studies indicate: 1) the induction/upregulation of FcεR on CD8+ T lymphocytes in vivo requires factors in addition to high serum IgE concentrations; 2) in addition to CD8+ FcεR+ T lymphocytes and monocytes, another, as yet unidentified, splenic cell component appears to contribute to the process by which ε-chain expression in IgE-secreting hybridoma cells is suppressed, and 3) a hybridoma (A3B1) that fails to induce CD8+, FcεR+ T lymphocytes in vivo and is not inhibited in IgE expression in vivo, nonetheless is inhibited in IgE expression in vitro when cocultured with spleen cells from mice with B53 tumors.

AB - Normal BALB/c mice injected i.p. with the IgE-secreting hybridomas B53 (ε,κ, anti-DNP), SE1.3 (ε,κ, anti-arsonate) or A3B1 (ε,κ, anti-TNP) were monitored for serum IgE concentrations and frequencies of splenic T lymphocytes with surface membrane receptors for the Fc portion of IgE (FcεR+ T lymphocytes). Mice with B53 or SE1.3 hybridomas initially developed high concentrations of IgE and CD8+ FcεR+ T lymphocytes, followed by a progressive decline in both serum IgE and expression of cytoplasmic ε-chains in the hybridoma cells. Serum IgE concentrations in mice with A3B1 hybridomas progressively increased without development of FcεR+ T lymphocytes nor a subsequent decline in IgE or change in cytoplasmic ε-chain expression in the A3B1 cells. An in vitro system in which the IgE-secreting hybridoma cells were cocultured with spleen cells harvested from mice with established B53 tumors was used to investigate the mechanisms involved in the inhibition of IgE production by the hybridoma cells. The results of these studies indicate: 1) the induction/upregulation of FcεR on CD8+ T lymphocytes in vivo requires factors in addition to high serum IgE concentrations; 2) in addition to CD8+ FcεR+ T lymphocytes and monocytes, another, as yet unidentified, splenic cell component appears to contribute to the process by which ε-chain expression in IgE-secreting hybridoma cells is suppressed, and 3) a hybridoma (A3B1) that fails to induce CD8+, FcεR+ T lymphocytes in vivo and is not inhibited in IgE expression in vivo, nonetheless is inhibited in IgE expression in vitro when cocultured with spleen cells from mice with B53 tumors.

UR - http://www.scopus.com/inward/record.url?scp=0025203688&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025203688&partnerID=8YFLogxK

M3 - Article

C2 - 2147197

AN - SCOPUS:0025203688

VL - 145

SP - 3610

EP - 3617

JO - Journal of Immunology

JF - Journal of Immunology

SN - 0022-1767

IS - 11

ER -